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Abstract
Background: In 1996, the National Cancer Institute hosted an international workshop to develop criteria to identify
patients with colorectal cancer who should be offered microsatellite instability (MSI) testing due to an increased
risk for Hereditary Nonpolyposis Colorectal Cancer (HNPCC). These criteria were further modified in 2004 and
became known as the revised Bethesda Guidelines. Our study aimed to retrospectively evaluate the percentage of
patients diagnosed with HNPCC tumors in 2004 who met revised Bethesda criteria for MSI testing, who were
referred for genetic counseling within our institution.
Methods: All HNPCC tumors diagnosed in 2004 were identified by accessing CoPath, an internal database. Both
the Tumor Registry and patients’ electronic medical records were accessed to collect all relevant family history
information. The list of patients who met at least one of the revised Bethesda criteria, who were candidates for MSI
testing, was then cross-referenced with the database of patients referred for genetic counseling within our
institution.
Results: A total of 380 HNPCC-associated tumors were diagnosed at our institution during 2004 of which 41
(10.7%) met at least one of the revised Bethesda criteria. Eight (19.5%) of these patients were referred for cancer
genetic counseling of which 2 (25%) were seen by a genetics professional. Ultimately, only 4.9% of patients eligible
for MSI testing in 2004 were seen for genetic counseling.
Conclusion: This retrospective study identified a number of barriers, both internal and external, which hindered
the identification of individuals with HNPCC, thus limiting the ability to appropriately manage these high risk
families.
Background
Hereditary Nonpolyposis Colorectal Cancer (HNPCC),
including Lynch syndrome (LS), is the most common
hereditary condition associated with colorectal cancer,
accounting for approximately 1-3% of all colorectal can-
cers [1-4]. In addition to early onset colorectal cancer
(CRC), with an estimated lifetime risk of 70% in LS
patients with a median age at diagnosis of 45 years,
other cancers integral to this syndrome include endome-
trial, stomach, small bowel, ovarian, hepatobiliary tract,
upper uroepithelial tract, and brain cancer [2,5,6]. Muir-
Torre syndrome is a variant of HNPCC characterized by
several cutaneous features including sebaceous adeno-
mas, sebaceous carcinomas, and multiple keratoacantho-
mas, in addition to visceral cancers [2].
LS follows an autosomal dominant mode of inheri-
tance, due to germline mutations in several DNA mis-
match repair (MMR) genes, predominantly MLH1 and
MSH2,b u ta l s oMSH6 and less frequently PMS2 [2,7].
MMR genes encode proteins involved in the identifica-
tion and repair of DNA mismatch errors, which inevita-
bly arise during DNA replication. Defects within this
pathway lead to microsatellite instability (MSI), the hall-
mark of HNPCC and LS tumors [8-10]. More than 90%
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or MLH1 mutations and 10-15% of sporadic colorectal
cancers demonstrate high microsatellite instability using
a panel of 5 microsatellite markers (MSH-H) [1,4,10-12].
MSI-H histology refers to characteristic histologic fea-
tures of CRC associated with defective DNA MMR and
includes a cribiform/solid (medullary) architectural pat-
tern, infiltrating lymphocytes intimately associated with
tumor cells, a Crohn’s-like lymphocytic reaction, and
mucinous/signet ring differentiation [13,14]. These his-
tologic features can thus further aid in the identification
of patients with HNPCC-associated colorectal cancer.
Given the high lifetime cancer risks associated with
HNPCC, optimal selection of individuals for genetic
screening and testing is paramount. Clinical criteria to
help identify families with LS were established in 1991
and revised in 1999 [6,15].
To clarify the role of genetics and to elucidate clinico-
pathologic criteria to determine which patients should
undergo genetic testing, the National Cancer Institute
hosted an international workshop in 1996 that outlined
a set of recommendations known as the Bethesda guide-
lines to help identify colorectal tumors that should be
tested for MSI [16]. In 2004, the guidelines were
amended and are the most accurate clinical criteria
tested to date for identifying patients at risk for HNPCC
[10,13,16,17] (see appendix 1). It has been estimated
that the Bethesda guidelines will potentially target 15-
20% of the total colorectal cancer burden [18]. Multiple
studies have subsequently evaluated the clinical perfor-
mance of the revised Bethesda guidelines and have con-
firmed that these recommendations constitute an
efficient, cost-effective, and accurate means to identify
patients at risk for HNPCC [11,17,19].
MSI testing could serve as a useful screening tool to
identify families who may harbor a cancer-predisposing
mutation for colorectal cancer, as well as other types of
cancer [17]. Identifying MSI-H tumors should prompt
referral for predictive genetic testing and with subse-
quent discovery of a gene mutation in select individuals,
should lead to intensive surveillance strategies with
improved outcomes for families with HNPCC [20,21].
The ability to identify these patients by applying the
revised Bethesda guidelines, followed by referral to a
genetics professional for microsatellite instability testing
and germline testing, if indicated, would presumably be
facilitated most readily in an institution that houses a
Cancer Genetics Program. In our quality assurance
study, we therefore aimed to retrospectively evaluate,
over the course of one year, the actual percentage of
patients diagnosed and treated for HNPCC-associated
tumors who met revised Bethesda criteria, making them
eligible for MSI testing, who were then referred for
genetic counseling services within our tertiary care
institution. This retrospective study also aimed to iden-
tify any barriers which may hinder the identification of
individuals with HNPCC.
Methods
The inclusion criteria for the study were adults, 18 years
of age or older, who were diagnosed at our institution
in 2004 with HNPCC-associated tumors including color-
ectal, endometrial, stomach, small intestine, ovarian,
pancreas, ureter and renal pelvis, biliary tract, brain
(glioblastoma) tumors, sebaceous gland adenomas/carci-
nomas and keratoacanthomas. Patients who were under
18 years of age or who had a diagnosis of familial ade-
nomatous polyposis (FAP) were excluded from the
study. Pathology specimens including carcinoid tumors,
stromal tumors, islet cell tumors, primary peritoneal
cancer, lymphoma, and brain tumors other than glio-
blastoma were also excluded since they are not typical
malignancies characteristic of Lynch syndrome (Henry
Lynch, personal communication).
All HNPCC-associated tumors diagnosed between
January 1, 2004 and December 31, 2004 were identified
by accessing CoPath, an internal database that classifies
and tracks all anatomic pathology specimens and
archives their gross and histologic findings. After identi-
fying all eligible cases, both the Tumor Registry and
each patient’s electronic medical record were then
accessed to gather all relevant family history informa-
tion. The revised Bethesda criteria were applied to each
patient case to determine which individuals fulfilled at
least one of the criteria that would warrant MSI testing.
The list of patients who met the revised Bethesda cri-
teria, and were thus eligible for MSI testing, were then
compared to those actually referred to the Cancer
Genetics Program as detailed in the Patient Referral
Database. Of those patients referred for cancer genetic
services, we then determined which patients followed
through with the genetics consult by accessing the
Patient Appointment Database. For those patients who
elected not to schedule an appointment for cancer
genetic counseling, their reasoning, if provided, was
documented in the Patient Referral Database.
Patient confidentiality was preserved and the study
posed minimal risk to subjects. Full approval was
obtained from the Human Subjects Protection Office
prior to conducting this study.
Results
As shown in Table 1, a total of 380 HNPCC-associated
tumors were diagnosed at our institution between Janu-
ary 1 and December 31, 2004. Of the 380 tumor cases,
111 were colorectal cancers, 18 were glioblastomas, 7
were ureteral and renal pelvis tumors, 64 were uterine
cancers, 36 were ovarian cancers, 21 were gastric
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tract cancers, 62 were pancreatic cancers, and 29 were
sebaceous adenomas or keratoacanthomas.
A total of 41 out of 380 cases (10.7%) met at least one
of the revised Bethesda criteria and consisted of 21 col-
orectal, 1 ureteral/renal pelvis, 2 uterine, 6 ovarian, 3
gastric, 3 small bowel, and 4 pancreatic cancers, along
with 1 keratoacanthoma case. In Table 1, the number in
parentheses represents the specific numbered criteria (1
through 5) met for each tumor type when the revised
Bethesda guidelines were applied.
Eight out of 41 patients who met at least 1 of the
revised Bethesda criteria were referred for cancer genetic
counseling, representing 19.5%. Of the 8 patients
referred, 2 (25%) were seen by a member of the Cancer
Genetics Program. The remaining 6 patients, although
referred, did not follow through with an appointment.
In some cases, the patients did not pursue genetic coun-
seling because their insurance company did not recog-
nize the credentials of the board certified genetic
counselor/medical geneticist, and thus would not cover
the consultation fee. Other patients did not pursue
genetic counseling because they 1) didn’ta p p r e c i a t et h e
potential benefits of the information, 2) expressed
ambivalence about learning the information that the test
could potentially provide and/or 3) expressed concerns
about the potential for insurance and/or employment
discrimination. Ultimately, only 4.9% of eligible patients
who met revised Bethesda criteria for MSI testing in
2004 were seen for genetic counseling within our
institution.
There were a large number of patients, 145 in total or
38% of all HNPCC tumor cases diagnosed in 2004, for
whom it was not possible to determine if their personal
and family history met at least one of the revised
Bethesda criteria. In 20 of these patients, all of whom
were diagnosed with colorectal cancer between 50 and
59 years of age, it was not possible to determine
whether they met criteria 3 of the revised Bethesda
guidelines since MSI-high histology was not consistently
reported by the pathologist(s). The remainder of the
‘unknown’ patients, 125 in total, had limited or
unknown family histories despite accessing both the
Tumor Registry and the patient’s medical record, thus
precluding our ability to apply the revised Bethesda
criteria.
Discussion
Our study highlights several barriers, in applying the
r e v i s e dB e t h e s d ac r i t e r i at oi d e n t i f yp a t i e n t sa tr i s kf o r
Lynch syndrome based on a diagnosis of an HNPCC
tumor. These barriers include limited family histories
captured by health care providers and inconsistent
reporting of MSI-H histology for colorectal cancer spe-
cimens by pathologists. Patient compliance represents
another barrier identified lack of insurance coverage for
genetic counseling services.
The results of our study demonstrate that 38% of
patients (145/380) have incomplete recording of their
family history of cancer and/or poorly characterized his-
tology, thus hindering the application of the revised
Bethesda criteria to determine eligibility for MSI testing.
For these 38% of patients, it remains unknown whether
they would have met the revised Bethesda criteria, had
more information been made available. While approxi-
mately 11% of all HNPCC-related tumors (41/380) diag-
nosed over the course of one year at our tertiary care
hospital met revised Bethesda criteria, only 20% of these
(8/41) were referred for cancer genetic counseling,
despite an active Cancer Genetics Program within our
institution. In some of these cases, the health care
provider did discuss consideration of cancer genetic
Table 1 Application of revised Bethesda guidelines to HNPCC tumors (2004)
Cases Meet Criteria (Criteria #)
2 Do Not Meet Criteria Unknown Total
Colorectal 21 (1, 2, 5) 39 51 111
Brain 0 11 7 18
Renal/Ureter 1 (5) 5 1 7
Uterus 2 (5) 46 16 64
Ovary 6 (2, 4, 5) 23 7 36
Stomach 3 (2, 4) 10 8 21
Small Bowel 3 (2, 4, 5) 7 9 19
Biliary 0 6 8 14
Pancreas 4 (2, 5) 31 27 62
Keratoacanthoma/SA
1 1 (2) 16 11 28
Total 41 194 145 380
1 Sebaceous adenoma
2 The number in parentheses represents the specific criteria met (1 through 5) for each tumor type when the revised Bethesda guidelines were applied.
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declined. Furthermore, among those patients referred, a
significant number did not follow through with the
counseling due to potential concerns for insurance and
employment discrimination, financial barriers created by
insurance companies, and possibly, a lack of apprecia-
tion for the long term benefits of surveillance and
primary prevention in families with a hereditary predis-
position to cancer.
The first major barrier we encountered in conduct-
ing this study was the cursory documentation of family
history data in the medical chart by practitioners. Age
at cancer diagnosis was rarely documented for rela-
tives, cancer histories for 2
nd and 3
rd degree relatives
were not recorded, and cancer types were not always
specified. We accessed our institutional Tumor Regis-
try database, which collects and maintains family his-
tory data on all patients first diagnosed and/or treated
for a malignancy. However, t h ed a t ac o l l e c t e dr e l i e s
solely on family history information previously
recorded in the patient chart. The Tumor Registry
does not directly interview patients. Furthermore, the
Commission on Cancer and the State Department of
Health does not mandate recording specific details
regarding family history. We found that detailed pedi-
gree information for extended relatives was not avail-
able. As a result, the application of the revised
Bethesda criteria depended mostly on the affected
patient’s past medical history information, as opposed
to family history information.
The ability to identify patients and their families at
risk for HNPCC is strongly dependent on the clinician’s
recognition, understanding and application of the
revised Bethesda criteria. These clinical criteria require
the compilation of a detailed and thorough family his-
tory, the simplest and potentially most essential diagnos-
tic task in assessing patients. Not surprisingly, previous
studies have shown that even when a family history was
suggestive of HNPCC, the significance of the data was
either not appreciated by the clinician or the potential
relevance of multiple HNPCC-related cancers in the
same individual was overlooked [22,23].
We also noted that the Tumor Registry does not keep
track of patients with non-melanoma skin cancers or
precancerous lesions. We identified a total of 28 kera-
toacanthoma and sebaceous adenoma patients from the
pathology database. In all instances dermatologists did
not record a family history that could be found in the
medical records. We identified one patient with a kera-
toacanthoma who met criteria #2 of the revised
Bethesda guidelines since she was diagnosed with a
metachronous colorectal cancer. This history, however,
was not recognized by the dermatologist and the patient
was not referred for cancer genetic counseling.
The low referral rate for cancer genetic counseling
may, therefore, be partly attributed to poor recognition
by clinicians of patients at-risk for HNPCC. Unlike sev-
eral of the polyposis syndromes, HNPCC lacks striking
phenotypic characteristics that would raise suspicion.
Clinicians, therefore, must rely heavily upon a well-
elucidated and well-documented family history, coupled
with knowledge regarding the natural history of HNPCC
and its association with multiple extracolonic tumors
[2]. In one cohort, endometrial cancer predated the
diagnosis of CRC in over 50% of HNPCC female
patients [24]. Moreover, in the United States several
cases have been successfully litigated when physicians
failed to identify a patient at risk for a hereditary cancer
predisposition syndrome [25].
Some practitioners may not appreciate the potential
benefits of genetic testing for patients with cancer and
their families. From a clinical management perspective,
a number of studies have highlighted the importance of
identifying patients and families with HNPCC. For
example, in one study of patients with HNPCC, Järvinen
et al. [21] showed that colorectal cancer surveillance
reduced the risk and improved the survival of colorectal
cancer in comparison to the control group who declined
surveillance. Schmeler et al. [20] showed that prophylac-
tic hysterectomy with bilateral salpingo-oophorectomy
was an effective strategy for preventing endometrial and
ovarian cancer in women with HNPCC. In comparison,
Lindor and colleagues [26] demonstrated that patients
who fulfill Amsterdam-1 criteria but without mismatch
repair deficiency, and their kindred, can receive less
intensive cancer surveillance than recommended for
HNPCC patients, because these families have a signifi-
cantly lower risk of colorectal cancer and no appreciable
risk of extracolonic cancers, similar to the general
population.
The second major barrier illuminated by our study was
the inconsistent reporting by pathologists of specific fea-
tures that define MSI-H histology repair. As a result of
these histologic features not routinely being documented,
it was not possible to analyze 20 of 111 colorectal cancer
specimens diagnosed from 50 to 59 years of age (criteria
#3). Following our request to retrospectively analyze
these features for these 20 cases, the pathologist con-
firmed that 2 demonstrated tumor-infiltrating lympho-
cytes and 2 exhibited Crohn’s-like lymphocytic reaction
(20%). Multiple studies have demonstrated an improved
prognosis in both sporadic and HNPCC cancers that
demonstrate MSI-H histology [2,27-33]. Further, mis-
match repair status predicted the benefit of adjuvant
fluorouracil chemotherapy in colorectal cancer [34,35].
Pathologists play a central role in identifying HNPCC
patients’ age <50 years and HNPCC histology and
could then reflex to MSI testing. This was proposed by
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cally for age and histologic features, they found that out
of 75 CRC cases examined, 23% were identified as
MSI-H tumors. Furthermore, although the positive pre-
dictive value of histology suggestive of MSI-H was low at
32%, a total of 80% of the MSI-H CRCs had at least one
of the criteria suggestive of MSI-H status [11]. An elec-
tronic reminder system for pathologists increased MSH
tumor and Lynch syndrome patient identification [36].
Lastly, among those patients ultimately referred to the
Cancer Genetics Program, few followed through with a
consultation. This represents the third major barrier for
the identification of HNPCC individuals. Unfortunately,
Medicare and other major insurers do not currently
provide payment for the board-certified medical profes-
sionals who are specifically trained to provide genetic
counseling about the risks, benefits and limitations of
testing. The American College of Medical Genetics and
the National Society of Genetic Counselors are actively
pursuing appropriate recognition of non-physician
genetics providers. So far, this has resulted in masters
and doctoral-trained genetics providers being eligible to
apply for a National Provider Identifier (NPI) through
the Centers for Medicare and Medicaid in 2006 and the
development of a CPT code (96040) for genetic counsel-
ing services, effective January 1, 2007. Patients may also
have concerns regarding the potential for insurance
and/or employment discrimination.
To circumvent the barrier identified by our study and
others, a more universal approach to molecular testing
for HNPCC has been advocated. To circumvent the lack
of detailed family history to identify HNPCC patients, a
model for MSI testing of selected CRC tumors was
found to be efficacious and cost-effective, identifying 2.2
times more patients compared to current practice [37].
In the study by Schofield et al. [38], MSI was used as an
initial LS screening test followed by immunohistochem-
istry of MMR genes from CRC patients less than
60 years of age. From a cohort of 1,344 patients, 3.6%
had germline mutations. Hampel et al. [39] evaluated
the feasibility of screening for Lynch syndrome for all
colorectal cancers. Limiting tumor analysis to patients
who fulfill the revised Bethesda criteria failed to identify
28% of cases with Lynch syndrome. Lastly, the Evalua-
tion of Genomic Applications in Practice and Prevention
(EGAPP) Working Group commissioned an evidence-
based review through the Agency for Healthcare
Research and Quality to better understand the utility of
DNA testing strategies in reducing morbidity and mor-
tality from Lynch syndrome. Following a review of 104
studies published through 2006, they found sufficient
evidence to recommend genetic testing for Lynch syn-
drome to all individuals with newly diagnosed colorectal
cancer [40]. This group concluded that such a strategy
could lead to improvement in medical management and
clinical outcomes not only for patients, but also their
relatives with Lynch syndrome. The EGAPP Working
Group recommendations should not be viewed as dis-
counting the value of family history but instead, adding
a new pathway to identify high risk families [41]. The
cost-effectiveness of four genetic testing strategies to
indentify Lynch syndrome patients was developed from
the U.S. healthcare system prospective. Universal testing
would detect nearly twice as many cases as targeting
younger patients with cost-effectiveness comparable
with other preventive services [42].
Potential pitfalls to universal testing include the inabil-
ity to definitively diagnose LS patients in an ever-
changing genotype and phenotype landscape. For exam-
ple, a recent series of LS families with MSH2 deficient
tumors without detectable MSH2 mutations were found
to have germ-line mutations in an upstream gene
encoding for Ep-CAM [43]. Would these individuals
previously been counseled as familial CRC type X [26]?
Expansion of the LS phenotype to include prostate and
bladder cancer has been documented, which increases
the number of persons to be tested[44,45]. The ability of
patients and at-risk relatives to deal with the emotional
and psychological burdens of the complexity and uncer-
tainty of genetic testing is understudied [46]. Finally, the
fragmented U.S. healthcare system does not provide a
central repository to carefully delineate the cancer risk
for specific gene mutations or alert carriers of mutations
of unknown significance should future research alter
today’s understanding of cancer risk.
Conclusions
Our study identified several major barriers to the appli-
cation of the revised Bethesda guidelines within our
institution. We propose several recommendations that
would allow the adoption of an improved systems-based
practice.
First, a detailed family history should be captured by
the initial health care provider who encounters the
patient and the data should be recorded in the patient’s
electronic medical record. Second, concerted efforts
need to be made to educate all providers about HNPCC
and the importance of the revised Bethesda guidelines
in identifying at-risk families. Third, emphasis should be
placed on the pivotal role that pathologists can play in
identifying at-risk patients by their consistent reporting
of MSI histology. A departmental/institutional policy
could be adopted that would direct pathologists to apply
the MSI-H histology to all colorectal cancer specimens
with subsequent recommendations when MSI testing
should be pursued. Lastly, measures should be taken on
a national level to eliminate barriers experienced by
patients referred for genetic counseling. Continued
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and employment discrimination by educating patients
and providers about the Genetic Information Non-dis-
crimination Act (GINA).
Overcoming the barriers identified in our study will
enhance the detection of patients with Lynch syndrome,
via the more traditional approach of high risk individuals
being referred by astute clinical providers for considera-
tion of genetic counseling and testing. In contrast, the
EGAPP Working Group recommendations support a pub-
lic health approach in which seemingly low risk individuals
are screened in order to identify those high risk individuals
within the population. These two approaches should be
viewed as complementary, rather than one followed to the
exclusion of the other, in order to optimize the identifica-
tion of patients and their families with Lynch syndrome.
Appendix 1 (Umar et al. [13])
Revised Bethesda guidelines for testing colorectal tumors
for MSI
Tumors from individuals should be tested for MSI in
the following situations:
1. Colorectal cancer diagnosed in a patient who is
less than 50 yr of age
2. Presence of synchronous, metachronous colorec-
tal, or other HNPCC-associated tumors (colorectal,
endometrial, stomach, ovarian, pancreas, ureter and
renal pelvis, biliary tract, small bowel, brain, and
sebaceous gland adenomas and keratoacanthomas),
regardless of age
3. Colorectal cancer with the MSI-high histology
(presence of tumor-infiltrating lymphocytes,
Crohn’s-like lymphocytic reaction, mucinous/signet
ring differentiation, or medullary growth pattern)
diagnosed in a patient who is less than 60 yr of age
4. Colorectal cancer diagnosed in one or more first-
degree relatives with an HNPCC-related tumor, with
one of the cancers being diagnosed under age 50 yr
5. Colorectal cancer diagnosed in two or more first-
or second-degree relatives with HNPCC-related
tumors, regardless of age
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